Skip to main content
SUPN logo

SUPN

Supernus Pharmaceuticals, Inc.
$47.94 +0.70 (+1.48%) At close · Jul 7
Market Cap
$2.78B
Shares
58,039,721

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$718.95M +8.6%
FY2025 Revenue FY2010–FY2025
Net Income
-$38.55M -152.2%
FY2025 Net Income FY2010–FY2025
Gross Margin
89.63% +1.4pp
FY2025 Gross Margin FY2013–FY2025
Operating Margin
-8.66% -21pp
FY2025 Operating Margin FY2010–FY2025
Diluted EPS
-$0.68 -151.5%
FY2025 Diluted EPS FY2012–FY2025
Operating Cash Flow
$47.33M -72.5%
FY2025 Operating Cash Flow FY2010–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
$840M – $870M $776.83M $718.95M $661.82M $607.52M $667.24M $579.78M $520.4M $392.76M $408.9M $302.24M $215M $147.47M $92.68M $12.02M $1.48M $803K $106K
$82.19M $74.56M $77.91M $83.78M $87.22M $52.46M $16.66M $15.36M $15.22M $11.99M $8.42M $5.76M $1.1M
$694.64M $644.39M $583.91M $523.74M $580.02M $467.94M $376.1M $393.54M $287.02M $203.02M $139.04M $86.92M $10.92M
89.63% 88.23% 86.21% 86.93% 89.92% 95.76% 96.24% 94.97% 94.43% 94.29% 93.79% 90.81%
$118.75M $106.24M $108.8M $91.59M $74.55M $90.47M $75.96M $69.1M $89.21M $49.58M $42.79M $29.14M $19.59M $17.25M $23.52M $30.63M $35.15M
$520.79M $485.56M $321.58M $336.36M $377.22M $304.76M $200.68M $153.25M $154.7M $137.91M $106.01M $89.06M $72.61M $55.59M $20.13M $7.93M $5.08M
$95.31M $89.46M $77.98M $82.39M $82.63M $29.99M $15.7M $5.18M $5.19M $6.9M $1.3M $200K $200K $229K $229K $229K $229K
$97.31M $91.56M $80.41M $84.86M $85.54M $32.6M $18.14M $6.66M $7.06M $8.13M $2.4M $921K $928K $742K $871K $879K $1.19M
$837.19M $781.24M $580.15M $612.79M $621.11M $493.75M $346.7M $244.18M $264.45M $202.7M $160.79M $126.62M $97.96M $73.94M $43.65M $38.56M $40.23M
-$60.36M -$62.28M $81.67M -$5.27M $46.12M $86.03M $173.7M $148.57M $144.44M $99.54M $54.22M $20.84M -$5.28M -$61.92M -$42.17M -$37.75M -$40.12M
-8.66% 12.34% -0.87% 6.91% 14.84% 33.38% 37.83% 35.33% 32.93% 25.22% 14.13% -5.69% -515.18% -2849.26% -4701.37% -37851.89%
$36.95M $29.28M $162.08M $79.59M $131.67M $118.62M $191.84M $155.23M $151.51M $107.67M $56.62M $21.77M -$4.35M -$61.18M -$41.3M -$36.87M -$38.94M
$0 $0 $2.42M $7.07M $19.7M $19.44M $18.21M $13.84M $134K $543K $1.23M $4.96M $7.85M $3.58M $1.87M
$13.84M $2.86M $1.47M $681K $348K $299K $120K $31K $107K
$11.21M $13.25M $16.2M $8.04M $14.62M -$12.85M -$5.05M -$1.08M -$4.27M $1.08M -$3.85M -$6.23M -$5.02M -$30.35M -$4.12M -$1.72M $649K
-$49.15M -$49.03M $97.87M $2.77M $60.74M $73.18M $168.65M $147.49M $140.18M $100.62M $50.37M $14.61M -$10.3M -$92.27M -$46.28M -$39.47M -$39.47M
-$20.13M -$10.48M $24.01M $1.45M $32K $19.75M $41.7M $34.43M $29.18M $43.33M -$40.85M $666K $630K $0 $0 -$16.25M -$399K
-$29.02M -$38.55M $73.87M $1.32M $60.71M $53.42M $126.95M $113.06M $110.99M $57.28M $91.22M $13.94M -$10.93M -$92.27M -$46.28M $53.82M -$38.46M
-5.36% 11.16% 0.22% 9.1% 9.21% 24.39% 28.79% 27.14% 18.95% 42.43% 9.46% -11.79% -767.73% -3127.3% 6701.74% -36285.85%
-$38.55M $73.87M $1.32M $64.27M $53.42M $126.95M $113.06M $110.99M $57.28M $91.22M $13.94M -$10.93M -$92.27M -$47.43M $50.39M -$41.89M
-$29.11M -$38.41M $74.27M $3.93M $55.96M $45.99M $128.51M $123.63M $108.58M $56.67M $91.58M $13.61M -$11.08M -$92.22M -$46.34M $53.82M -$38.47M
USD/shares -$0.68 $1.34 $0.02 $1.13 $1.01 $2.41 $2.16 $2.13 $1.13 $1.84 $0.29 -$0.26 -$2.90 -$2.72
USD/shares -$0.68 $1.32 $0.02 $1.04 $0.98 $2.36 $2.10 $2.05 $1.08 $1.76 $0.28 -$0.26 -$2.90 -$2.72
shares 56.45M 55.1M 54.54M 53.67M 53.1M 52.62M 52.41M 51.99M 50.76M 49.47M 47.49M 42.26M 31.85M 17.44M 1.61M 1.59M
shares 56.45M 55.96M 55.51M 61.68M 54.36M 53.69M 53.82M 54.1M 53.3M 51.71M 51.16M 42.26M 31.85M 17.44M 1.61M 1.59M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Reportable Segment $718,952,000 $661,817,000 $607,521,000 $667,238,000

By Product & Service (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Product $626,536,000 $637,696,000 $573,933,000 $567,504,000 $509,350,000 $383,400,000 $399,871,000
Qelbree $304,654,000 $241,273,000 $140,192,000 $61,322,000 $9,879,000 $0 $0
GOCOVRI $146,824,000 $130,824,000 $119,637,000 $104,421,000 $9,778,000 $0 $0
Collaboration Revenue $52,996,000 $0 $0
APOKYN $47,771,000 $73,926,000 $75,083,000 $75,305,000 $99,233,000 $74,296,000 $0
Trokendi XR $42,421,000 $63,201,000 $94,336,000 $261,221,000 $304,817,000 $319,640,000 $295,214,000 $315,295,000
Oxtellar XR $40,700,000 $99,464,000 $113,404,000 $115,345,000 $110,708,000 $98,725,000 $88,186,000 $84,576,000
Royalty License and Other Revenue $39,420,000 $24,121,000 $33,588,000
Manufactured Product Other $26,912,000 $29,008,000 $31,281,000 $31,818,000 $33,089,000 $16,689,000
ONAPGO $17,254,000 $0 $0
MYOBLOC $19,514,000 $9,746,000 $0
Osomolex ER $188,000 $0 $0
XADAGO $13,387,000 $6,943,000 $0
License $750,000
Royalty $33,588,000 $17,806,000 $12,271,000 $11,047,000 $9,355,000 $8,276,000
Key facts CIK 1356576 CUSIP 868459108 13F (30d) 8 filings 7 filers Visit website Investor relations